MedTrace Logo

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

NCT04434937 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-10-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma

Conditions

Interventions

DRUG

parsaclisib

parsaclisib will be taken orally QD with water without regard to food except on mornings of PK clinic visits

Sponsors & Collaborators

  • Incyte Biosciences Japan GK

    lead INDUSTRY

Principal Investigators

  • Incyte Medical Monitor · Incyte Biosciences Japan GK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2023-02-16
Completion
2023-10-13
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04434937 on ClinicalTrials.gov